Acceleron garners $31M Series C

Just months after raising its second venture round, Acceleron Pharma has announced a $31 million Series C. Much of that money will be used to advance its ACE-011 program for bone growth into a mid-stage trial. A Phase I study of ACE-031 is planned to gauge its effectiveness increasing muscle mass and strength. A third candidate--ACE-041--is scheduled for the clinic in the second half of next year. Acceleron has made headlines for its work with the Belgian blue, a bull with enormous muscles.

Bessemer Venture Partners led the round along with other new investors MPM BioEquities and QVT Financial. All existing institutional investors participated in the round including Advanced Technology Ventures, Flagship Ventures, OrbiMed Advisors, Polaris Ventures, Sutter Hill Ventures and Venrock.

- see Acceleron's release for more

ALSO: Relypsa, a spinout of Ilypsa, has raised $33 million in its first round of funding. Amgen acquired Ilypsa in June for $420 million. 5AM Ventures and New Leaf Venture Partners led the round for the company, which is being led by two former Ilypsa execs. Release

Related Articles:
The race is on for muscle-enhancing therapies. Report
Acceleron takes a lesson from the giant Belgian blue. Report
Acceleron garners $30M in venture capital. Report

Suggested Articles

Shorla Pharma picked up $8.3 million to push its cancer programs through U.S. regulatory approval and gear up for its first drug launch in 2021.

Nodthera bagged $55 million to get its lead asset through phase 1 and into proof-of-concept studies, and a second program into the clinic.

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.